Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32722
Title: New daily persistent headache: A systematic review and meta-analysis.
Austin Authors: Cheema, Sanjay;Mehta, Dwij;Ray, Jason Charles;Hutton, Elspeth J;Matharu, Manjit Singh
Affiliation: Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.
The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Department of Neurology, Alfred Health, Melbourne, Australia.
Department of Neuroscience, Monash University, Melbourne, Australia.
Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.
Department of Neuroscience, Monash University, Melbourne, Australia.
Neurology
Issue Date: May-2023
Publication information: Cephalalgia : an International Journal of Headache 2023; 43(5)
Abstract: To perform a systematic review and meta-analysis of the epidemiology, precipitants, phenotype, comorbidities, pathophysiology, treatment, and prognosis of primary new daily persistent headache. We searched PubMed/Medline, EMBASE, Cochrane, and clinicaltrials.gov until 31 December 2022. We included original research studies with any design with at least five participants with new daily persistent headache. We assessed risk of bias using National Institutes of Health Quality Assessment Tools. We used random-effects meta-analysis where suitable to calculate pooled estimates of proportions. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis compliant study is registered with PROSPERO (registration number CRD42022383561). Forty-six studies met inclusion criteria, predominantly case series, including 2155 patients. In 67% (95% CI 57-77) of cases new daily persistent headache has a chronic migraine phenotype, however new daily persistent headache has been found to be less likely than chronic migraine to be associated with a family history of headache, have fewer associated migrainous symptoms, be less vulnerable to medication overuse, and respond less well to injectable and neuromodulatory treatments. New daily persistent headache is a well described, recognisable disorder, which requires further research into its pathophysiology and treatment. There is a lack of high-quality evidence and, until this exists, we recommend continuing to consider new daily persistent headache a distinct disorder.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32722
DOI: 10.1177/03331024231168089
ORCID: 0000-0002-5438-6549
0000-0003-4833-5507
0000-0002-4960-2294
Journal: Cephalalgia : an International Journal of Headache
Start page: 3331024231168089
PubMed URL: 37032616
ISSN: 1468-2982
Type: Journal Article
Subjects: NDPH
chronic daily headache
disease classification
headache precipitants
phenotype
Headache Disorders/epidemiology
Headache Disorders/therapy
Headache Disorders/diagnosis
Migraine Disorders/diagnosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Jun 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.